Article Details

Cyxone receive regulatory approval to start clinical Rabeximod Phase 2b study in rheumatoid arthritis

Retrieved on: 2022-09-19 09:40:03

Tags for this article:

Click the tags to see associated articles and topics

Cyxone receive regulatory approval to start clinical Rabeximod Phase 2b study in rheumatoid arthritis. View article details on hiswai:

Excerpt

September 19, 2022 I Cyxone (publ), a biotech company in autoimmune diseases, have received approvals from the Medical Product Agency (Office for ...

Article found on: pipelinereview.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up